Friday, November 9, 2012
Cellceutix Corp., of Beverly, Mass., said patient dosing was initiated in a Phase I trial with Kevetrin, its anti-cancer drug candidate, at Harvard University's Dana Farber Cancer Center and Beth Israel Deaconess Medical Center.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.